Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

There's a telling anecdote about Pro Medicus that doesn't appear in any investor presentation. Radiologists at top US hospitals have started demanding it as a condition of employment — they simply won't join institutions that don't run Visage, the company's flagship imaging platform. That's an extraordinary thing for any B2B software to achieve. It's the kind of product loyalty that doesn't come from marketing; it comes from genuinely making someone's working day meaningfully better.

What the business actually does

Every time a patient gets an MRI, CT scan, or X-ray at a major hospital, a radiologist has to open, load, and analyse that image — often dozens or hundreds per day. The software that makes this possible is called a PACS (Picture Archiving and Communication System), and for decades it was dominated by clunky, slow legacy systems sold by hardware giants like GE and Philips. These systems were built for a different era: they require images to fully download before they can be viewed, which is increasingly painful as scan files grow larger with higher-resolution technology.

Pro Medicus solved this with a fundamentally different approach. Rather than downloading the image to the radiologist's workstation, Visage streams it server-side — like Netflix rather than a DVD. The result is images that load 60-70% faster than competing systems, with the radiologist able to start reviewing before the file has even fully transferred. In a profession where reading hundreds of scans a day is standard, that speed translates directly into throughput — institutions report radiologists handling 20-25% more cases on Visage than on legacy platforms.

The business model amplifies this. Pro Medicus doesn't charge a flat licence fee — it charges per scan viewed (a "transaction" model), meaning revenue grows automatically as imaging volumes rise. The company is paid every time a radiologist clicks. Once embedded in a hospital's clinical workflow, the switching costs are enormous: replacing a PACS system means retraining every radiologist, migrating years of archived images, and disrupting a mission-critical clinical function. This is reflected in one remarkable statistic: Pro Medicus has had a 100% customer renewal rate since 2009. Not one hospital has ever left.

The story ahead

Here's what makes Pro Medicus genuinely exciting as an investment: despite being the #1 rated enterprise imaging product in its category (ranked by KLAS Research, the healthcare IT equivalent of Gartner), it still holds only around 8% of the US market. Of the top 25 US hospital networks — the Integrated Delivery Networks (IDNs) that collectively represent the most valuable contracts — only four currently run Visage. The company's strategy has been deliberate: win the most prestigious academic medical centres first (Mayo Clinic, Memorial Sloan Kettering, NYU Langone, Mass General Brigham), then use those as proof points to move downstream into IDNs and private radiology groups.

That strategy is now paying off at scale. In FY2025, Pro Medicus signed $520M in new contracts, headlined by a $330M, 10-year deal with Trinity Health — one of the largest not-for-profit hospital systems in the US. The significance of Trinity isn't just its size; it's that Trinity operates across 26 states, meaning Visage will become the daily tool for radiologists across a vast network, further cementing its reputation as the preferred platform and making it harder for rival IDNs to justify choosing anything else.

Beyond radiology, Pro Medicus is opening a second growth front: cardiology. In July 2025, it signed a $170M, 10-year contract with UCHealth that explicitly includes cardiology imaging — the first major cardiology deployment in the company's history. The cardiology imaging market is roughly one-fifth the size of radiology by volume, but scan complexity and pricing means it could generate 2-3x the revenue per case. Europe represents a third runway; Pro Medicus has operated there for years through its German business but has barely scratched the surface of a market that mirrors the US opportunity.

The financial picture

The numbers reflect a business firing on all cylinders. FY2025 revenue reached $213M — up 32% year-on-year — with net profit of $115M, implying a net margin above 54%. The company carries no debt and sits on $210M in cash. Its margins are structural, not cyclical: because Visage is a software-only model with near-zero incremental cost per additional customer, every new hospital added is almost pure profit at the margin.

The most recent half-year result (H1 FY2026) caused a significant share price selloff — revenue of $128.9M came in slightly below analyst consensus, and the stock fell sharply from its $336 peak to approximately $120 today — a drawdown of over 60%. This is worth examining rather than dismissing. The miss was largely attributed to contract timing: large, multi-year implementations are inherently lumpy, and revenue from significant contracts signed in late FY2025 had not yet come online. CEO Sam Hupert was explicit in noting that the pipeline "remains strong" and that the second half would see stronger revenue recognition as implementations complete.

Here's a detail the headline selloff obscures: H1 FY2026 EPS came in at $1.64 for just six months. Annualised, that implies Pro Medicus is currently earning roughly $3.28 per share — meaning the stock trades at approximately 37x forward earnings. That is the lowest earnings multiple Pro Medicus has traded at in nearly a decade. It is still not cheap in absolute terms, but for a business compounding earnings at 30%+ annually with zero customer churn, 74% operating margins, and $220M in net cash, it is meaningfully less demanding than its history suggests.

Valuation: three scenarios

The following scenarios are built off a trailing twelve-month revenue base of approximately $240M AUD.

Bear case — growth decelerates to 15% annually. This assumes hospital procurement slows, implementation timelines lengthen, and competition intensifies. Revenue reaches ~$480M by FY2030, with net margins compressing slightly to 50%. Earnings of ~$240M at a 45x terminal multiple implies a market cap of ~$10.8B — roughly $103 per share. That's modest downside from current prices, suggesting the bear case is already largely priced in.

Base case — growth continues at 25% annually. This reflects continued US IDN penetration, early cardiology contributions, and modest European progress. Revenue reaches ~$730M by FY2030, margins hold at 55%. Earnings of ~$400M at a 55x multiple implies a market cap of ~$22B, or approximately $210 per share — roughly 75% upside from today over five years, without requiring anything heroic from the business.

Bull case — growth accelerates to 35% annually. Cardiology scales faster than expected, a major European IDN is won, and market share capture from GE and Philips accelerates. Revenue approaches $1.1B by FY2030, net margins expand to 58%. Earnings of ~$625M at a 65x multiple implies a market cap of ~$40B, or approximately $385 per share — roughly 220% upside. This is not the base case, but it is not unreasonable given the trajectory.

The bear case is worth taking seriously

The honest caveat: at any price, Pro Medicus is a premium business trading at a premium multiple. If AI genuinely disrupts radiologist workflows faster than expected, demand for PACS software could evolve in unpredictable ways. US hospital systems facing budget pressure may delay upgrades. The company is also heavily concentrated in North America (over 85% of revenue), meaning it carries meaningful macro and FX exposure. And if revenue growth moderates below 25% for consecutive periods, multiple compression could offset earnings growth entirely.

The bottom line

My central estimate for fair value is $210 AUD per share, derived from the base case: 25% annual revenue growth to ~$730M by FY2030, 55% net margins, and a 55x earnings multiple reflecting the quality of the franchise. Against today's price of ~$120, that implies approximately 75% upside over five years. The bear case (~$103) suggests limited further downside from here; the bull case (~$385) reflects the optionality embedded in cardiology and Europe if execution continues.

At $120, the stock offers an asymmetric setup: you are not buying a distressed company — you are buying a best-in-class franchise that has temporarily disappointed quarterly expectations in a business where revenue is inherently lumpy. The contract backlog, the renewal rate, the margin profile, and the expanding addressable market have not changed. The price has.

For investors with a five-year horizon and a tolerance for volatility, the current entry point is the most compelling Pro Medicus has offered in years.